腸内フローラのダイナミズム

出版社： 医薬出版
著者：
発行日： 2016-08-25
分野： 基礎医学  >  医動物(寄生虫)
ISBN： 9784990673949
電子書籍版： 2016-08-25 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

5,280 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

3,168 円(税込)

購入する

目次

  • 腸内フローラのダイナミズム

    ―目次―

    特別講演1．生物間にわたる内分泌系：
    　　　　　　心血管代謝疾患の発症における腸内細菌由来の
    　　　　　　内分泌物質の役割

    特別講演2．肝硬変と腸内細菌：臨床の側面から

    講演1．食物繊維由来腸内細菌代謝産物、
    　　　　単鎖脂肪酸とエネルギー代謝

    講演2．肥満により増加する腸内細菌の代謝産物による肝癌促進機構

    講演3．腸腎連関：腸内環境と腎不全の相互作用

    講演4　ヒトマイクロバイオームからの診断バイオマーカーの探索：
    　　　　結腸直腸がんの事例

    講演5　前立腺がん予防に関するイソフラボン代謝腸内細菌

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

特別講演1. 生物間にわたる内分泌系 : 心血管代謝疾患の発症における腸内細菌由来の内分泌物質の役割

P.11 掲載の参考文献
1) Bornfeldt KE, Tabas I : Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab 2011, 14 : 575-585
 
2) Demarco VG, Aroor AR, Sowers JR : The pathophysiology of hypertension in patients with obesity. Nat. Rev. Endocrinol. 2014 doi : 10. 1038/nrendo. 2014. 44.
 
3) Agrawal V, et al. : Impact of treating the metabolic syndrome on chronic kidney disease. Nat. Rev. Nephrol, 2009, 5 : 520-528
 
4) Calle EE, Kaaks R : Overweight, obesity and cancer : epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer 2004, 4 : 579-591
 
5) Turnbaugh PJ, et al. : An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444 : 1027-1031
 
6) Ridaura VK, et al. : Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 2013, 341 : 1241214.
PubMed
7) Henao-Mejia J, et al. : Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012, 482 : 179-185
 
8) Jumpertz R, et al. : Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am. J. Clin. Nutr. 2011, 94 : 58-65
 
9) Turnbaugh PJ, et al. : A core gut microbiome in obese and lean twins. Nature 2009, 457 : 480-484
 
10) Turnbaugh PJ, et al. : Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 2008, 3 : 213-223
 
11) Backhed F, et al. : Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc. Natl. Acad. Sci. USA 2007, 104 : 979-984
 
12) Ley RE, et al. : Microbial ecology : human gut microbes associated with obesity. Nature 2006, 444 : 1022-1023
 
13) Ley RE, et al : Obesity alters gut microbial ecology. Proc. Natl. Acad. Sci. USA 2005, 102 : 11070-11075
 
14) Backhed F, et al. : The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl. Acad. Sci. USA 2004, 101 : 15718-15723
 
15) Greiner T, Backhed F : Effects of the gut microbiota on obesity and glucose homeostasis. Trends Endocrinol. Metab. 2011, 22 : 117-123
 
16) Joyce SA, et al. : Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut. Proc. Natl. Acad. Sci USA 2014, 111 : 7421-7426
 
17) Kimura I, et al. : The gut microbiota suppresses insulin-mediated fat accumulation via the shortchain fatty acid receptor GPR43. Nat. Commun. 2013, 4 : 1829
PubMed
18) Gao Z, et al. : Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 2011, 58 : 1509-1517
 
19) De Vadder F, et al. : Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 2014, 156 : 84-96
 
20) Brown AJ, et al. : The orphan G protein-coupled receptors GPR41 and GRP43 are activated by proprionate and other short chain carboxylic acids. J. Biol. Chem. 2003, 278 : 11312-11319
 
21) Thaiss CA, et al. : Transkingdom control of microbiota diurnal oscillations promotes metabolic homeostasis. Cell 2014, 159 : 514-529
 
22) Cox LM, Blaser MJ : Antibiotics in early life and obesity. Nat. Rev. Endocrinol. (In Press) 2014
 
23) Li Q, et al. : Synchronous evolution of an odor biosynthesis pathway and behavioral response. Curr. Biol. 2013, 23 : 11-20
 
24) Wallrabenstein I, et al. : Human trace amine-associated receptor TAAR5 can be activated by trimethylamine. PLoS One 2013, 8 : e54950
PubMed
25) Maguire JJ, et al. : International Union of Pharmacology. LXXII. Recommendations for trace amine associated receptor nomenclature. Pharmacol. Rev. 2009, 61 : 1-8
 
26) Brown JM, Hazen SL : Metaorganismal nutrient metabolism as a basis of cardiovascular disease. Curr. Opin. Lipidol. 2014, 25 : 48-53
 
27) Brown JM, Hazen SL : The gut microbial endocrine organ : bacterially-derived signals driving cardiometabolic disease. Ann. Rev Med. (In Press) 2015
 
28) Hazen SL, Brown JM : Eggs as a dietary source for gut microbial production of trimethylamine-N-oxide. Am. J. Clin. Nutr. 2014, 100 : 741-743
 
29) Warrier M, et al. : The TMAO generating enzyme flavin monooxygenase 3 is a central regulator of cholesterol balance. Cell Rep. (In Press) 2015
 
30) Shih DM, et al. : Flavin containing monoxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis. J. Lipid Res. 2015, 56 : 22-37
 
31) Wang Z, et al. : Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011, 472 : 57-63
 
32) Koeth RA, et al. : Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 2013, 19 : 576-585
 
33) Koeth, RA et al. : γ-butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO. Cell Metab. 2014, 20 : 799-812
 
34) Tang WH, et al. : Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N. Engl. J. Med. 2013, 368 : 1575-1578
 
35) Wang Z, et al. : Prognostic value of choline and betaine depends on intestinal microbiotagenerated metabolite trimethylamine-N-oxide. Eur. Heart J. 2014, 35 : 904-910
 
36) Bennett BJ, et al. : Trimethylamine-1v-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab. 2013, 17 : 49-60
 
37) Tang WH, et al. : Prognostic value of elevated levels of intestinal microbe-generated metabolite, trimethylamine-N-oxide, in patients with heart failure : refining the gut hypothesis. J. Am. Coll. Cardiol. 2014, 64 : 1908-1914
 
38) Hartiala J, et al. : Comparative genome-wide association studies in mice and humans for trimethylamine-N-oxide, a proatherogenic metabolite of choline and L-carnitine. Arterioscler, Thromb. Vasc. Biol. 2014, 34 : 1307-1313
 
39) Wang Z, et al. : Measurement of trimethylamine-N-oxide by stable isotope dilution liquid chromatography tandem mass spectrometry. Anal. Biochem. 2014, 455 : 35-40
 
40) Berrington de Gonzalez A, et al. : Body-mass index and mortality among 1.46 million white adults. N. Engl. J. Med. 2010, 363 : 2211-2219
 
41) Bauer UE, et al. : Prevention of chronic disease in the 21st century : elimination of the leading preventable causes of premature death and disability in the USA. Lancet 2014, 384 : 45-52
 
42) Willett WC : Dietary fats and coronary heart disease. J. Intern. Med. 2012, 272 : 13-24
 
43) Eckel RH : Clinical practice. Nonsurgical management of obesity in adults. N. Engl. J. Med. 2008, 358 : 1941-1950
 
44) Stumvoll M, et al. : Type 2 diabetes : principles of pathogenesis and therapy. Lancet 2005, 365 : 1333-1346
 
45) Bartelt A, Heeren J : Adipose tissue browning and metabolic health. Nat. Rev. Endocrinol. 2014, 10 : 24-36
 
46) Wu J, Cohen P, Spiegelman BM : Adaptive thermogenesis in adipocytes : is beige the new brown? Genes Dev. 2013, 27 : 234-250
 
47) Harms M, Seale P : Brown and beige fat : development, function and therapeutic potential. Nat. Med. 2013, 19 : 1252-1263
 
48) Long JZ, et al. : A smooth muscle-like origin for beige adipocyte. Cell Metab. 2014, 19 : 810-820
 
49) Cypess AM et al. : Identification and importance of brown adipose tissue in adult humans. N. Engl. J. Med. 2009, 360 : 1509-1517
 
50) van Marken Lichtenbelt WD et al. : Cold-activated brown adipose tissue in healthy men. N. Engl. J. Med. 2009, 360 : 1500-1508
Medical*Online
51) Virtanen KA et al. : Functional brown adipose tissue in healthy adults. N. Engl. J. Med. 2009, 360 : 1518-1525
 
52) Cypress AM, et al. : Activation of human brown adipose tissue by a β3-adrenergic receptor agonist. Cell Metab. 2015, 21 : 33-38
 
53) Nedergaard J, et al. : Unexpected evidence for active brown adipose tissue in adult humans. Am. J. Physiol. Endocrinol. Metab. 2007, 293 : E444-E452
 
54) Alonso-Magdalena P, et al. : Endocrine disruptors in the etiology of type 2 diabetes mellitus. Nat. Rev. Endocrinol. 2011, 7 : 346-353
 
55) Potthoff MJ, et al. : Endocrine fibroblast growth factors 15/19 and 21 : from feast to famine. Genes Dev. 2012, 26 : 312-324
 
56) Owen BM, et al. : Tissue-specific actions of the metabolic hormones FGF 15/19 and FGF21. Trends Endocrinol. Metab. 2015, 26 : 22-29
 
57) Kahn BB, et al. : AMP-activated protein kinase : ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005, 1 : 15-25
 
58) Murray S, et al. : Hormonal and neural mechanisms of food reward, eating behavior and obesity. Nat. Rev. Endocrinol. 2014, 10 : 540-552
 
59) Shuldiner AR, et al. : Resistin, obesity and insulin resistance-the emerging role of the adipocyte as an endocrine organ. M. Engl. J. Med. 2001, 345 : 1345-1346
 
60) Morrison RF, Farmer SR : Hormonal signaling and transcriptional control of adipocyte differentiation. J. Nutr. 2000, 130 : 3116S-3121S
 
61) Unger RH : Glucagon physiology and pathophysiology. N. Engl. J. Med. 1971, 285 : 443-449
 
62) Cherrington AD, et al. : Physiological consequences of phasic insulin release in the normal animal. Diabetes 2002, 51 : Suppl., S103-S108
 
63) Habegger KM, et al. : The metabolic actions of glucagon revisited. Nat. Rev Endocrinol. 2010, 6 : 689-697
 
64) Leavens KF, Birnbaum MJ : Insulin signaling to hepatic lipid metabolism in health and disease. crit. Rev. Biochem. Mol. Biol. 2011, 46 : 200-215
 
65) Inagaki T, et al. : Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005, 2 : 217-225
 
66) Kir S, et al. : FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 2011, 331 : 1621-1624
 
67) Potthoff MJ, et al. : FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREBPGC-1a pathway. Cell Metab. 2011, 13 : 729-738
 
68) Inagaki T, et al. : Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 2007, 5 : 415-425
 
69) Inagaki T, et al. : Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metab. 2008, 8 : 77-83
 
70) Craciun S, Balskus EP : Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme. Proc. Natl. Acad. Sci. USA 2012, 109 : 21307-21312
 
71) Craciun S, et al. : Characterization of choline trimethylamine-lyase expands the chemistry of glycyl radical enzymes. ACS Chem. Biol. 2014, 9 : 1408-1413
 
72) Zhu Y, et al. : Carnitine metabolism to trimethylamine by an unusual Rieske-type oxygenase from human microbiota. Proc. Natl. Acad. Sci. USA 2014, 111 : 4268-4273
 
73) Olayioye MA, et al. : StarD10, a START domain protein overexpressed in breast cancer, functions as a phospholipid transfer protein. J. Biol. Chem. 2005, 280 : 27436-27442
 
74) Olayioye MA, et al. : Phosphorylation of StarD10 on serine 284 by casein kinase II modulates its lipid transfer activity. J. Biol. Chem. 2007, 282 : 22492-22498
 
75) Ito M, et al. : Disruption of Stard10 gene alters the PPARα-mediated bile acid homeostasis. Biochim. Biophys. Acta. 2013, 1831 : 459-468
 
76) Danis P, Farkas R : Hormone-dependent and hormone-independent control of metabolic and developmental functions of malate dehydrogenase-review. Endocr. Regul, 2009, 43 : 39-52
 
77) Musrati RA : Malate dehydrogenase : distribution, function, and properties. Gen. Physiol. Biophys. 1998, 17 : 193-210
 
78) Leturque A, et al. : GLUT2 mutations, translocation, and receptor function in diet sugar management. Am. J. Endocrinol. Metab. 2009, 296 : E985-E992
 
79) Kellett GL, et al. : Sugar absorption in the intestine : the role of GLUT2. Annu. Rev. Nutr. 2008, 28 : 35-54
 
80) Choi JH, et al. : Thrap3 docks on phosphoserine 273 of PPARγ and controls diabetic gene programming. Genes Dev. 2014, 28 : 2361-2369
 
81) Katano-Toki A, et al. : THRAP3 interacts with HELZ2 and plays a novel role in adipocyte differentiation. Mol. Endocrinol. 2013, 27 : 769-780
 
82) Maliekal P, et al. : Molecular identification of mammalian phosphopentomutase and glucose-1, 6-bisphosphate synthase, two members of the alpha-D-phosphohexomutase family. J. Biol. Chem. 2007, 282 : 31844-31851
 
83) Xavier MA, et al. : Phosphoglucomutase is an in vivo lithium target in yeast. J. Biol. Chem. 2001, 276 : 37794-37801
 
84) Zhang Q, et al. : Insulin-like growth factor II signaling through the insulin-like growth factor II/mannose-6-phosphate receptor promotes exocytosis in insulin-secreting cells. Proc. Natl. Acad. Sci. USA 1997, 94 : 6232-6237
 
85) Nakae J, et al. : Distinct and overlapping functions of insulin and IGF-I receptors. Endocr Rev. 2001, 22 : 818-835
 
86) Carter JR, Kennedy EP : Enzymatic synthesis of cytidine diphosphate diglyceride. J. Lipid Res. 1966, 7 : 678-683
 
87) D'Souza K, et al. : Distinct properties of the two isoforms of CDP-diacylglycerol synthase. Biochemistry 2014, 53 : 7358-7367
 
88) Lam P, et al. : The bile salt export pump : clinical and experimental aspects of genetic and acquired cholestatic liver disease. Semin. Liver Dis. 2010, 30 : 125-133
 
89) Carlton VE, et al. : Molecular basis of intrahepatic cholestasis. Ann. Med. 2004, 36 : 606-617
 

特別講演2. 肝硬変と腸内細菌 : 臨床の側面から

P.26 掲載の参考文献
1) Lozupone CA, Stombaugh JI, Gordon JI, et al. : Diversity, stability and resilience of the human gut microbiota. Nature 2012, 489 : 220-230
 
2) Tyler AD, Smith MI, Silverberg MS : Analyzing the human microbiome : a "how to" guide for physicians. Am J Gastroenterol 2014, 109 : 983-993
 
3) Gillevet P, Sikaroodi M, Keshavarzian A, et al. : Quantitative assessment of the human gut microbiome using multitag pyrosequencing. Chem Biodivers 2010, 7 : 1065-1075
 
4) Segata N, Izard J, Waldron L, et al. : Metagenomic biomarker discovery and explanation. Genome Biol 2011, 12 : R60
PubMed
5) Tandon P, Garcia-Tsao G. : Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 2008 ; 28 : 26-42
 
6) Mazagova M, Wang L, Anfora AT, et al. : Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice. FASEB J 2014.
PubMed
7) Schuppan D, Afdhal NH. : Liver cirrhosis. Lancet 2008, 371 : 838-851
 
8) Cirera I, Bauer TM, Navasa M, et al. : Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol 2001, 34 : 32-37
 
9) Llovet JM, Bartoli R, March F, et al. : Translocated intestinal bacteria cause spontaneous bacterial peritonitis in cirrhotic rats : molecular epidemiologic evidence. J Hepatol 1998, 28 : 307-313
 
10) Gupta A, Dhiman RK, Kumari S, et al. : Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J Hepatol 2010, 53 : 849-855
 
11) Nava GM, Stappenbeck TS. : Diversity of the autochthonous colonic microbiota. Gut Microbes 2011, 2.
PubMed
12) Bajaj JS, Heuman DM, Hylemon PB, et al. : Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 2014, 60 : 940-947
 
13) Chen Y, Guo J, Qian G, et al. : Gut dysbiosis in acute-on-chronic liver failure and its predictive value for mortality. J Gastroenterol Hepatol 2015.
 
14) Bajaj JS, Ridlon JM, Hylemon PB, et al. : Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol 2012, 302 : G168-175
 
15) Bajaj JS, Hylemon PB, Ridlon JM, et al. : Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol 2012, 303 : G675-685
 
16) Tuomisto S, Pessi T, Collin P, et al. : Changes in gut bacterial populations and their translocation into liver and ascites in alcoholic liver cirrhotics. BMC Gastroenterol 2014, 14 : 40
PubMed
17) Rogers GB, van der Gast CJ, Bruce KD, et al. : Ascitic microbiota composition is correlated with clinical severity in cirrhosis with portal hypertension. PLoS One 2013, 8 : e74884
PubMed
18) Bajaj JS, Betrapally NS, Hylemon PB, et al. : Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy. Hepatology 2015.
PubMed
19) Bajaj JS, Betrapally NS, Hylemon PB, et al. : Gut microbiota alterations can predict hospitalizations in cirrhosis independent of diabetes mellitus. Sci Rep 2015, 5 : 18559
PubMed
20) Ridlon JM, Alves JM, Hylemon PB, et al. : Cirrhosis, bile acids and gut microbiota : unraveling a complex relationship. Gut Microbes 2013, 4 : 382-387
 
21) Bajaj JS, Cox IJ, Betrapally NS, et al. : Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function. Am J Physiol Gastrointest Liver Physiol 2014.
PubMed
22) Bajaj JS, Gillevet PM, Patel NR, et al. : A longitudinal systems biology analysis of lactulose withdrawal in hepatic encephalopathy. Metab Brain Dis 2012, 27 : 205-215
 
23) Kakiyama G, Pandak WM, Gillevet PM, et al. : Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol 2013, 58 : 949-955
 
24) Lin CY, Tsai IF, Ho YP, et al. : Endotoxemia contributes to the immune paralysis in patients with cirrhosis. J Hepatol 2007, 46 : 816-826
 
25) Qin N, Yang F, Li A, et al. : Alterations of the human gut microbiome in liver cirrhosis. Nature 2014, 513 : 59-64
 
26) Huang HJ, Zhang AY, Cao HC, et al. : Metabolomic analyses of faeces reveals malabsorption in cirrhotic patients. Dig Liver Dis 2013, 45 : 677-682
 
27) Lunia MK, Sharma BC, Sharma P, et al. : Probiotics prevent hepatic encephalopathy in patients with cirrhosis : a randomized controlled trial. Clin Gastroenterol Hepatol 2014, 12 : 1003-8 el
 
28) Bass NM, Mullen KD, Sanyal A, et al. : Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010, 362 : 1071-1081
 
29) Victor DW, 3rd, Quigley EM. : Microbial therapy in liver disease : probiotics probe the microbiome-gutliver-brain axis. Gastroenterology 2014, 147 : 1216-1218
 
30) Bajaj JS, Heuman DM, Sanyal AJ, et al. : Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One 2013, 8 : e60042
PubMed
31) Dhiman RK, Rana B, Agrawal S, et al. : Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis : a randomized, controlled trial. Gastroenterology 2014, 147 : 1327-1337 e3
 
32) Bajaj JS, Heuman DM, Hylemon PB, et al. : Randomised clinical trial : Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Aliment Pharmacol Ther 2014, 39 : 1113-1125
 
33) Wiest R, Chen F, Cadelina G, et al. : Effect of Lactobacillus-fermented diets on bacterial translocation and intestinal flora in experimental prehepatic portal hypertension. Dig Dis Sci 2003, 48 : 1136-1141
 
34) Degirolamo C, Rainaldi S, Bovenga F, et al. : Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice. Cell Rep 2014, 7 : 12-18
 
35) Chavez-Tapia NC, Tellez-Avila FI, Garcia-Leiva J, et al. : Use and overuse of proton pump inhibitors in cirrhotic patients. Med Sci Monit 2008, 14 : CR468-72
 
36) O'Leary JG, Reddy KR, Wong F, et al. : Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. Clin Gastroenterol Hepatol 2014.
PubMed
37) Zhang Y, Limaye PB, Renaud HJ, et al. : Effect of various antibiotics on modulation of intestinal microbiota and bile acid profile in mice. Toxicol Appl Pharmacol 2014, 277 : 138-145
 
38) Bajaj JS. : The role of microbiota in hepatic encephalopathy. Gut Microbes 2014, 5 : 397-403
 
39) Chen Y, Yang F, Lu H, et al. : Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 2011, 54 : 562-572
 
40) Zhang Z, Zhai H, Geng J, et al. : Large-scale survey of gut microbiota associated with MHE via 16S rRNA-based pyrosequencing. Am J Gastroenterol 2013, 108 : 1601-1611
 
41) Lu H, Wu Z, Xu W, et al. : Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients. Microb Ecol 2011, 61 : 693-703
 
42) Grat M, Holowko W, Wronka KM, et al. : The relevance of intestinal dysbiosis in liver transplant candidates. Transpl Infect Dis 2015, 17 : 174-184
 
43) Aggarwal R, Goel A, Sarangi AN, et al. : Effect of lactulose administration on gut microbiota in patients with liver cirrhosis. Hepatology 2014, 60 : 382A
 

講演1. 食物繊維由来腸内細菌代謝産物, 短鎖脂肪酸とエネルギー代謝

P.33 掲載の参考文献
1) Kasubuchi M, Hasegawa S, Hiramatsu T, et al. : Dietary gut microbial metabolites, short-chain fatty acids, and host metabolic regulation. Nutrients 2015, 7 : 2839-2849
 
2) Hara T, Kashihara D, Ichimura I, et al. : Role of free fatty acid receptors in the regulation of energy metabolism. Biochim Bioph. vs Acta 2014, 1841 : 1292-1300
 
3) Kimura I, Inoue D, Maeda T, et al. : Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41). Proc Natl Arad Sci USA 2011, 108 : 8030-8035
 
4) Inoue D, Kimura I, Wakabayashi M, et al. : Short-chain fatty acid receptor GPR41-mediated activation of sympathetic neurons involves synapsin 2b phosphorylation. FEBS Lett 2012, 586 : 1547-1554
 
5) Kimura I, Ozawa K, Inoue D, et al. : The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun 2013, 4 : 1829
PubMed
6) Samuel BS, Shaito A, Motoike T, et al. : Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc. Natl. Acad. Sci. USA 2008, 105 : 16767-16772
 
7) Tolhurst G, Heffron H, Lam YS, et al. : Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 2012, 61 : 364-371
 
8) Chambers ES, Viardot A, Psichas A, et al. : Effects of targeted delivery of propionate to the human colon on apetite regulation, body weight mainteinance and adiposity in overweight adults. Gut 2014, 64 : 1744-1754
 
9) De Vadder F, Kovatcheva-Datchary P, Goncalves D, et al. : Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 2014, 156 : 84-96
 
10) Zaibi MS, Stocker CJ, O'Dowd J, et al. : Roles of GPR41 and GPR43 in leptin secretory responses of murine adipocytes to short chain fatty acids. FEBS Lett 2010, 584 : 2381-2386
 
11) Tang C, Ahmed K, Gille A, et al. : Loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetes. Nat. Med 2015, 21 : 173-177
 
12) McNelis JC, Lee YS, Mayoral R, et al. : GPR43 potentiates β-cell function in obesity. Diabetes 2015, 64 : 3203-3217
 
13) Singh N, Guray A, Sivaprakasam S, et al : Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunidy, 2014, 40 : 128-139
 
14) Pluznick JL, Protzko RJ, Gevorgyan H, et al : Olfactory receptor responding to gut microbiota-derived signals plays a role in rennin secretion and blood pressure regulation. Proc. Natl. Acad. Sci. USA 2013, 110 : 4410-4415
 
15) Furusawa Y, Obata Y, Fukuda S, et al : Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013, 504 : 446-450
 
16) Kishino S, Takeuchi M, Park SB, et al : Polyunsaturated fatty acid saturation by gut lactic acid bacteria affecting host lipid composition. Proc. Natl. Acad. Sci. USA 2013, 110 : 17808-17813
 
17) Ichimura A, Hirasawa A, Poulain-Godefroy O, et al. : Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature 2012, 483 : 350-354
 
18) Miyamoto J, Mizukure T, Park SB, et al. : A gut microbial metabolite of linoleic acid, 10-hydroxy-cis-12-octadecenoic acid, ameliorates intestinal epithelial barrier impairment partially via GPR40-MEK-ERK pathway. J Biol Chem 2015, 290 : 2902-2918
 

講演2. 肥満により増加する腸内細菌の代謝産物による肝癌促進機構

P.43 掲載の参考文献
1) Cenit MC, Matzaraki V, Tigchelaar EF, Zhernakova A : Rapidly expanding knowledge on the role of the gut microbiome in health and disease. Biochim Biophys Acta 2014, 1842 : 1981-1992
 
2) Khandekar M J, Cohen P & Spiegelman B M : Molecular mechanisms of cancer development in obesity. Nature Rev. Cancer 2011, 11 : 886-895
 
3) Calle E E & Kaaks R : Overweight, obesity and cancer : epidemiological evidence and proposed mechanisms. Nature Rev. Cancer 2004, 4 : 579-591
 
4) Michelotti GA, Machado MV, Diehl AM : NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 2013, 10 : 656-665
 
5) Yoshimoto S, Yoshimoto S, Loo TM, Atarashi K, et al. : Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013, 499 : 97-101
 
6) Ohtani N and Hara E : Roles and mechanisms of cellular senescence in regulation of tissue homeostasis. Cancer Sci. 2013, 104 : 525-530
 
7) Coppe Jp, Patil CK, Rodier F et al. : Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 2008, 6 : 2853-2868
 
8) Kuilman T and Peeper DS : Senescence-messaging secretome : SMS-ing cellular stress. Nature Rev. Cancer 2009, 9 : 81-94
 
9) Park E J et al. : Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010, 140 : 197-208
 
10) Ohtani N, Imamura Y, Yamakoshi K, et al. : Visualizing the dynamics of p21waf1/Cip1 cyclin-dependent kinase inhibitor expression in living animals. Proc. Natl. Sci. USA 2007, 104 : 15034-15039
 
11) Sato Y, Murase K, Kato J, et al. : Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol 2008, 26 : 431-442
 
12) Ley RE, Turnbaugh PJ, Klein S, et al. : Microbial ecology : human gut microbes associated with obesity. Nature 2006, 444 : 1022-1023
 
13) Dapito DH, Mencin A, Gwak GY, et al. : Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012, 21 : 504-516
 
14) Ridlon JM, Kang DJ, Hylemon PB : Bile salt biotransformations by human intestinal bacteria. J Lipid Res. 2006, 47 : 241-259
 
15) Payne CM, Weber C, Crowley-Skillicorn C, et al. : Deoxycholate induces mitochondrial oxidative stress and activates NF-kappaB through multiple mechanisms in HCT-116 colon epithelial cells. Carcinogenesis 2007, 28 : 215-222
 
16) Takuma Y & Nouso K : Nonalcoholic steatohepatitis-associated hepatocellular carcinoma : our case series and literature review. World J. Gastroenterol 2010, 16 : 1436-1441
 
17) Rafter JJ, Child P, Anderson AM, et al. : Cellular toxicity of fecal water depends on diet. Am. J. Clin. Nutr. 1987, 45 : 559-563
 
18) David LA, Maurice CF, Carmody RN et al. : Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014, 505 : 559-563
 

講演3. 腸腎連関 : 腸内環境と腎不全の相互作用

P.51 掲載の参考文献
1) Vanholder R, De Smet R : Pathophysiologic effects of uremic retention solutes. J Am Soc Nephrol 1999, 10 : 1815-1823
 
2) Vanholder R, Baurmeister U, Brunet P, Cohen G, Glorieux G, Jankowski J : A bench to bedside view of uremic toxins. J Am Soc Nephrol 2008, 19 : 863-870
 
3) Kawakami T, Inagi R, Wada T, Tanaka T, Fujita T, Nangaku M : Indoxyl sulfate inhibits proliferation of human proximal tubular cells via endoplasmic reticulum stress. Am J Physiol Renal Physiol 2010, 299 : F568-F576
 
4) Chiang CK, Tanaka T, Inagi R, Fujita T, Nangaku M : Indoxyl sulfate, a representative uremic toxin, suppresses erythropoietin production in a HIF-dependent manner. Lab Invest 2011, 91 : 1564-1571
 
5) Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W : Review on uremic toxins : classification, concentration, and interindividual variability. Kidney Int 2003, 63 : 1934-1943
 
6) Clemente JC, Ursell LK, Parfrey LW, Knight R : The impact of the gut microbiota on human health : an integrative view. Cell 2012, 148 : 1258-1270
 
7) Vaziri. ND, Wong. J, Pahl. M, Piceno. YM, Yuan. J, Desantis, TZ, Ni. Z, Nguyen. TH, Andersen. GL : Chronic kidney disease alters intestinal microbial flora. Kidney Int 2013, 83 : 308-315
 
8) Vaziri ND, Yuan J, Rahimi A, Zhenmin Ni. Said. H, Subramanian VS : Disintegration of colonic epithelial tight junction in uremia : a likely cause of CKD-associated inflammation. Nephrol Dial Transplant 2012, 27 : 2686-2693
 
9) Akar H, Akar GC, Carrero JJ, Stenvinkel P, Lindholm B : Systemic consequences of poor oral health in Chronic kidney disease patients. Clin J Am SOC Nephrol 2011, 6 : 218-226
 
10) Kalman RS, Pedrosa MC : Evidence-based review of gastrointestinal bleeding in the chronic kidney disease patient. Semin Dial 2015, 28 : 68-74
 
11) Carter D, Einheber A, Bauer H, Rosen H, Burns WF : The role of the microbial flora in uremia. II. Uremic colitis, cardiovascular lesions, and biochemical observations. J Exp Med 1966, 123 : 251-266
 
12) Akizawa T, Asano Y, Morita S, Wakita T, Onishi Y, Fukuhara S, Gejyo F, Matsuo S, Yorioka N, Kurokawa K : Effect of a carbonaceous oral adsorbent on the progression of CKD : a multicenter, randomized, controlled trial. Am J Kidney Dis 2009, 54 : 459-467
 
13) Schulman G, Berl T, Beck GJ, Remuzzi G, Ritz E, Arita K, Kato A, Shimizu M : Randomized placebo-controlled EPPIC trials of AST-120 in CKD. J Am Soc Nephrol 2015, 26 : 1732-1746
 
14) Gibson GR, Probert HM, Loo JV, Rastall RA, Roberfroid MB : Dietary modulation of the human colonic microbiota : updating the concept of prebiotics. Nutr Res Rev 2004, 17 : 259-275
 
15) Furuse SU, Ohse T, Jo-Watanabe A, Shigehisa A, Kawakami K, Matsuki T, Chonan O, Nangaku M : Galacto-oligosaccharides attenuate renal injury with microbiota modification. Physiol Rep 2014, 2 : e12029
PubMed

講演4. ヒトマイクロバイオームからの診断バイオマーカーの探索 : 結腸直腸がんの事例

P.59 掲載の参考文献
1) Yu, J., et al. : Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut 2015.
PubMed
2) Arumugam, M., et al. : Enterotypes of the human gut microbiome. Nature 2011, 473 : 174-180
 
3) Findley, K. , et al. : Topographic diversity of fungal and bacterial communities in human skin. Nature 2013, 498 : 367-370
 
4) Human Microbiome Project Consortium : Structure, function and diversity of the healthy human microbiome. Nature 2012, 486 : 207-214
 
5) Qin, J., et al. : A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010, 464 : 59-65
 
6) Cho, I. and Blaser, M. J. : The human microbiome : at the interface of health and disease. Nat Rev Genet 2012, 13 : 260-270
 
7) Sonnenburg, J. L. and Fischbach, M. A. : Community health care : therapeutic opportunities in the human microbiome. Sci Transl Med 2011, 3 : 78ps12
PubMed
8) Guarner, F. and Malagelada, J. -R. : Gut flora in health and disease. The Lancet 2003, 361 : 512-519
 
9) Karlsson, F. H. , et al. : Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 2013, 498 : 99-103
 
10) Qin, J., et al. : A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012, 490 : 55-60
 
11) Le Chatelier, E, et al. : Richness of human gut microbiome correlates with metabolic markers. Nature 2013, 500 : 541-546
 
12) Turnbaugh, P. J., et al. : A core gut microbiome in obese and lean twins. Nature 2009, 457 : 480-484
 
13) Karlsson, F. H. , et al. : Symptomatic atherosclerosis is associated with an altered gut metagenome. Nature communications 2012, 3 : 1245
PubMed
14) Wang, Z., et al. : Gut Hora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011, 472 : 57-63
 
15) Smits, L. P. , et al. : Therapeutic potential of fecal microbiota transplantation. Gastroenterology 2013, 145 : 946-953
 
16) Tvede, M. , Tinggaard, M. and Helms, M. : Rectal bacteriotherapy for recurrent Clostridium difficile-associated diarrhoea : results from a case series of 55 patients in Denmark 2000-2012. Clinical Microbiology and Infection : the official publication of the european Society of Clinical Microbiology and Infectious Diseases 2015, 21 : 48-53
 
17) Khanna, S., et al. : A Novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection. Journal of Infectious Diseases 2016.
 
18) Stewart, E. J. : Growing unculturable bacteria. J Bacteriol 2012, 194 : 4151-4160
 
19) Handelsman, J., et al. : The new science of metagenomics : revealing the secrets of our microbial planet. The National Academies Press, Washington, DC, 2007.
 
20) Gill, S. R. , et al. : Metagenomic analysis of the human distal gut microbiome. Science 2006, 312 : 1355-1359
 
21) Kurokawa, K., et al. : Comparative metagenomics revealed commonly enriched gene sets in human gut microbiomes. DNA Res 2007, 14 : 169-181
 
22) Qin, N., et al. : Alterations of the human gut microbiome in liver cirrhosis. Nature 2014, 513 : 59-64
 
23) Castellarin, M. , et al. : Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Research 2012, 22 : 299-306
 
24) Kostic, A. D., et al. : Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Research 2012, 22 : 292-298
 
25) Kostic, Aleksandar D., et al. : Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host & Microbe 2013, 14 : 207-215
 
26) Rubinstein, M. R, et al. : Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. Cell Host & Microbe 2013, 14 : 195-206
 
27) Zackular, J. P., et al. : The human gut microbiome as a screening tool for colorectal cancer. cancer Prevention Research 2014, 7 : 1112-1121
 
28) Zeller, G., et al. : Potential of fecal microbiota for early-stage detection of colorectal cancer. Mol Syst Biol 2014, 10 : 766
PubMed
29) Feng, Q., et al. : Gut microbiome development along the colorectal adenoma-carcinoma sequence. Nature Communications 2015, 6 : 6528
PubMed
30) Ciccarelli, FD., et al. : Toward automatic reconstruction of a highly resolved tree of life. Science 2006, 311 : 1283-1287
 

講演5. 前立腺がん予防に関するイソフラボン代謝腸内細菌

P.68 掲載の参考文献
1) Appt SE : Usefulness of the monkey model to investigate the role soy in postmenopausal women's health. ILAR J. 2004, 45 : 200-211
 
2) He J, Wang S, Zhou M, Yu W, Zhang Y, He X : Phytoestrogens and risk of prostate cancer : a meta-analysis of observational studies. World J. Surg. Oncol. 2015, 13 : 231
 
3) Toi M, Hirota S, Tomotaki A, Sato N, Hozumi Y, Anan K, Nagashima T, Tokuda Y, Masuda N, Ohsumi S, Ohno S, Takahashi M, Hayashi H, Yamamoto S, Ohashi Y : Probiotic beverage with soy isoflavone consumption for breast cancer prevention : a case-control study. Curr. Nutr. Food Sci. 2013, 9 : 194-200
 
4) Takagi A, Kano M, Kaga C : Possibility of breast cancer prevention : use of soy isoflavones and fermented soy beverage produced using Probiotics. Int. J. Mol. Sci. 2015, 16 : 10907-10920
 
5) Ohta A, Uehara M, Sakai K, Takasaki M, Adlercreutz H, Morohashi T, Ishimi Y : A combination of dietary fructooligosaccharides and isoflavone conjugates increases femoral bone mineral density and equol production in ovariectomized mice. J. Nutr. 2002, 132 : 2048-2054
 
6) Uehara M : Isoflavone metabolism and bone-sparing effects of daidzein-metabolites. J. Clin. Biochem. Nutr. 2013, 52 : 193-201
 
7) Liu Z-M, Ho SC, Chen Y-M, Liu J, Woo J : Cardiovascular risks in relation to daidzein metabolizing phenotypes among Chinese postmenopausal women. PLoS One 2014, 9 : e87861
 
8) Ko K, Kim C-S, Ahn Y, Park S-J, Kim Y-J, Park JK, Lim Y, Yoo K, Kim SS : Plasma isoflavone concentration is associated with decreased risk of type 2 diabetes in Korean women but not men : results from the Korean Genome and Epidemiology Study. Diabetologia 2014
 
9) Wong JM, Kendall CW, Marchie A, Liu Z, Vidgen E, Holmes C, Jackson C, Josse RG, Pencharz PB, Rao AV, Vuksan V, Singer W, Jenkins DJ : Equol status and blood lipid profile in hyperlipidemia after consumption of diets containing soy foods. Am. J. Clin. Nutr. 2012, 95 : 564-571
 
10) Lukaczer D, Darland G, Tripp M, Liska D, Lerman RH, Schiltz B, Bland JS : Clinical effects of a proprietary combination isoflavone nutritional supplement in menopausal women : a pilot trial. Altern. Ther. Health Med. 2005, 11 : 60-65
 
11) Watanabe S, Terashima K, Sato Y, Arai S, Eboshida A : Effects of isoflavone supplement on healthy women. Biofactors 2000, 12 : 233-241
 
12) Jackson RL, Greiwe JS, Schwen RJ : Emerging evidence of the health benefits of S-equol, an estrogen receptor β agonist. Nutr. Rev. 2011, 69 : 432-448
 
13) Arora A, Nair MG, Strasburg GM : Antioxidant activities of isoflavones and their biological metabolites in a liposomal system. Arch. Biochem. Biophys. 1998, 356 : 133-141
 
14) Setchell KDR, Clerici C, Lephart ED, Cole SJ, Heenan C, Castellani D, Wolfe BE, Nechemias-Zimmer L, Brown NM, Lund TD, Handa RJ, Heubi JE : S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am. J. Clin. Nutr. 2005, 81 : 1072-1079
 
15) Lund TD, Munson DJ, Haldy ME, Setchell KDR, Lephart ED, Handa RJ : Equol is a novel anti-androgen that inhibits prostate growth and hormone feedback. Biol. Reprod. 2004, 70 : 1188-1195
 
16) Miyanaga N, Akaza H, Hinotsu S, Fujioka T, Naito S, Namiki M, Takahashi S, Hirao Y, Horie S, Tsukamoto T, Mori M, Tsuji H : Prostate cancer chemoprevention study : an investigative randomized control study using purified isoflavones in men with rising prostate-specific antigen. Cancer Sci. 2012, 103 : 125-130
 
17) Akaza H, Miyanaga N, Takashima N, Naito S, Hirao Y, Tsukamoto T, Mori M : Is daidzein non-metabolizer a high risk for prostate cancer? A case-controlled study of serum soybean isoflavone concentration. Jpn. J. Clin. Oncol. 2002, 32 : 296-300
 
18) Akaza H, Miyanaga N, Takashima N, Naito S, Hirao Y, Tsukamoto T, Fujioka T, Mori M, Kim W, Song JM, Pantuck AJ : Comparisons of percent equol producers between prostate cancer patients and controls : case-controlled studies of isoflavones in Japanese, Korean and American residents. Jpn. J. Clin. Oncol. 2004, 34 : 86-89
 
19) Tsuji H, Moriyama K Nomoto K, Miyanaga N, Akaza H : Isolation and characterization of the equol-producing bacterium Slackia sp. strain NATTS. Arch. Microbiol. 2010, 192 : 279-287
 
20) Maruo T, Sakamoto M, Ito C, Toda T, Benno Y : Adlercreutzia equolipaciens gen. nov., sp. nov., an equol-producing bacterium isolated from human faeces, and emended description of the genus Eggerthella. Int. J. Syst. Evol. Microbiol. 2008, 58 : 1221-1227
 
21) Minamida K, Ota K, Nishimukai M, Tanaka M, Abe A, Sone T, Tomita F, Hara H, Asano K : Asaccharobacter celatus gen. nov., sp. nov., isolated from rat caecurn. Int. J. Syst. Evol. Microbiol. 2008, 58 : 1238-1240
 
22) Tamura M, Hori S, Nakagawa H : Intestinal bacterium TM-30 : an S-equol-producing bacterium isolated from human feces is involved in estrogen metabolism in vitro. Food Sci. Technol. Res. 2014, 20 : 309-316
 
23) Matthies A, Blaut M, Braune A : Isolation of a human intestinal bacterium capable of daidzein and genistein conversion. Appl. Environ. Microbiol. 2009, 75 : 1740-1744
 
24) Jin J, Kitahara M, Sakamoto M, Hattori M, Benno Y : Slackia equolifaciens sp. nov., a human intestinal bacterium capable of producing equol. Int. J. Syst. Evol. Microbiol. 2010, 60 : 1721-1724
 
25) Wang X-L, Hur H-G, Lee JH, Kim KT, Kim S-I : Enantioselective synthesis of S-equol from dihydrodaidzein by a newly isolated anaerobic human intestinal bacterium. Appl. Environ. Microbiol. 2005, 71 : 214-219
 
26) Yokoyama S, Suzuki T : Isolation and characterization of a novel equol-producing bacterium from human feces. Biosci. Biotechnol. Biochem. 2008, 72 : 2660-2666
 
27) Tsuji H, Moriyama K, Nomoto K, Akaza H : Identification of an enzyme system for daidzein-to-equol conversion in Slackia sp. strain NATTS. Appl. Environ. Microbiol. 2012, 78 : 1228-1236
 
28) Fujimoto K, Tanaka M, Hirao Y, Nagata Y, Mori M, Miyanaga N, Akaza H, Kim W-J : Age-stratified serum levels of isoflavones and proportion of equol producers in Japanese and Korean healthy men. Prostate Cancer Prostatic Dis. 2008, 11 : 252-257
 
29) Kano M, Takayanagi T, Harada K, Sawada S, Ishikawa F : Bioavailability of isoflavones after ingestion of soy beverages in healthy adults. J. Nutr. 2006, 136 : 2291-2296
 
30) Yokoyama S, Niwa T, Osawa T, Suzuki T : Characterization of an O-desmethylangolensin-producing bacterium isolated from human feces. Arch. Microbiol. 2010, 192 : 15-22
 
31) Hur HG, Lay JO, Beger RD, Freeman JP, Rafii F : Isolation of human intestinal bacteria metabolizing the natural isoflavone glycosides daidzin and genistin. Arch. Microbiol. 2000, 174 : 422-428
 
32) Hur HG, Beger RD, Heinze TM, Lay JO, Freeman JP, Dore J, Rafii F : Isolation of an anaerobic intestinal bacterium capable of cleaving the C-ring of the isoflavonoid daidzein. Arch. Microbiol. 2002, 178 : 8-12
 
33. 辻ら. 2015. エコール産生能の測定方法. 特願2015-212768
 
34) Nagata Y, Sonoda T, Mori M, Miyanaga N, Okumura K, Goto K, Naito S, Fujimoto K, Hirao Y, Takahashi A, Tsukamoto T, Akaza H : Dietary isoflavones may protect against prostate cancer in Japanese men. J. Nutr. 2007, 137 : 1974-1979
 

書評

最近チェックした商品履歴

Loading...